Systemic lupus erythematosus in pregnancy

Area of Science:

• Obstetrics and Gynecology
• Rheumatology
• Immunology

Background:

• Systemic lupus erythematosus (SLE) increases pregnancy complications and reduces fetal survival rates.
• Estrogen's role in stimulating SLE and shared risk factors with other conditions contribute to these complications.
• Earlier reports may have exaggerated risks compared to current findings.

Purpose of the Study:

• To review the risks and outcomes of pregnancy in women with SLE.
• To highlight advancements in managing SLE during pregnancy.
• To recommend screening protocols for identifying at-risk pregnancies.

Main Methods:

• Review of recent studies on SLE pregnancy outcomes.
• Analysis of factors influencing maternal and fetal well-being.
• Evaluation of current management strategies, including medication and monitoring.

Main Results:

• Improved SLE management with glucocorticoids and immunosuppressants has reduced pregnancy flares and improved fetal survival.
• Women in complete clinical remission of SLE experience the most favorable pregnancy outcomes.
• Screening for anti-Ro (SS-A) antibodies identifies fetuses at risk for cardiac conduction defects.
• Screening for LE-anticoagulant is recommended for women with a history of recurrent fetal loss.

Conclusions:

• Modern management has improved pregnancy outcomes for women with SLE.
• Comprehensive perinatal care, including expert monitoring and multidisciplinary consultation, is essential.
• Targeted antibody screening (anti-Ro/SS-A and LE-anticoagulant) is vital for risk identification and management.